Full Press Release Details
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development ofcadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences:
Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Thursday, February 26, 2026Time: 11:20 AM ETFormat: Presentation OnlyLocation: VirtualWebcast Link
TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Time: 9:50 AM ETFormat: Presentation and 1x1 MeetingsLocation: Boston, MAWebcast Link
AboutvTvTherapeuticsvTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led bycadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more atvtvtherapeutics.comor follow the company onLinkedInorX.
About CadisegliatinCadisegliatin (TTP399)is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies,cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.Cadisegliatinhas been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatinis under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.